Related Experiment Videos
Methotrexate therapy in rheumatoid arthritis
The West Virginia Medical Journal
|February 1, 1989
Summary
Methotrexate offers symptomatic relief and improves objective measures for severe rheumatoid arthritis (RA) patients unresponsive to conventional treatments. Toxicity is uncommon, making it a viable option when other therapies fail.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) significantly impacts Americans economically and socially.
- Many RA patients lack effective treatment options or are intolerant to existing therapies.
- Immunosuppressive drugs are often the primary treatment for refractory RA.
Purpose of the Study:
- To evaluate the efficacy and safety of methotrexate in patients with severe rheumatoid arthritis.
- To determine if methotrexate provides symptomatic relief and improves objective parameters in RA.
- To assess the role of methotrexate as a therapeutic option for RA when conventional treatments are insufficient.
Main Methods:
- Retrospective analysis of patient data.
- Assessment of symptomatic relief and objective parameters in RA patients treated with methotrexate.
- Evaluation of methotrexate toxicity in the study population.
Main Results:
- Methotrexate provided symptomatic relief in patients with severe rheumatoid arthritis.
- Objective parameters showed improvement in patients receiving methotrexate.
- Significant toxicity associated with methotrexate was uncommon.
Conclusions:
- Methotrexate is an effective treatment option for selected patients with severe rheumatoid arthritis.
- Consider methotrexate for RA patients who have exhausted conventional treatment measures.
- Methotrexate demonstrates a favorable benefit-risk profile for refractory rheumatoid arthritis.